pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,221 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1894Endpoints1467Fierce Biotech779BioSpace768BioPharma Dive556raps257onclive165fda recalls
therapy area
allOncology13097Rare Disease3403Immunology3069Cardiology2870Hematology2337Pulmonology2300Vaccines
  • Study finds rising patent thickets may slow generic drug competition
    A recent special communication in JAMA reports that the number of patents linked to FDA‑approved small‑molecule drugs has risen over the past 15 years. The increase is driven largely by non‑primary…
    raps · 1mo agoNeutral↗ source
  • FDA issues early alert on Philips Lumify ultrasound system software and connection problems
    The FDA’s Center for Devices and Radiological Health has released an Early Alert about a potential high‑risk issue with Philips Lumify diagnostic ultrasound devices. The problem involves either a s…
    fda medwatch · 1mo agoRegulatoryNegative↗ source
← prev
page 12 of 49
next →
126
fda medwatch117
globenewswire health73
fda press62
1892
Psychiatry & CNS1247
Ophthalmology1150
Endocrinology & Metabolism809
Pain801
Nephrology789
  • Oliva LLC recalls 250 units of Riad's Oliva to Go dips over undeclared sesame
    Oliva LLC of Bethlehem, Connecticut announced a voluntary recall of about 250 units of its Riad's Oliva to Go line, including Baba Ghanouj, Spicy Baba Ghanouj and Hummus. The recall was triggered…
    fda recalls · 1mo agoCRLNegative↗ source
  • Krasnyi Oktyabr Recalls Starfish Seafood Trio Over Listeria Risk
    Krasnyi Oktyabr Inc. of Brooklyn, New York announced a voluntary recall of its Starfish Seafood Trio, which includes cold smoked salmon, halibut and trout packaged in 8‑oz vacuum‑sealed packs. The…
    fda recalls · 1mo agoCRLNegative↗ source
  • Krasnyi Oktyabr Inc. Recalls Starfish Seafood Premium Cold Smoked Norwegian Salmon Sliced (227g/8oz) Because of Possible Health Risk
    Krasnyi Oktyabr Inc. of Brooklyn, New York, is voluntarily recalling STARFISH SEAFOOD PREMIUM COLD SMOKED NORWEGIAN SALMON SLICED (227g/8oz) packages, because the product has the potential to be co…
    fda recalls · 1mo ago↗ source
  • Argenx shares tumble 15% after Phase 3 Sjögren’s study of Vyvgart halted for futility
    Argenx reported that an independent monitoring board recommended stopping its Phase 3 trial of Vyvgart in Sjögren’s disease due to futility, based on an interim analysis. The decision came earlier…
    BioPharma Dive · 1mo agoNegative readoutNegative↗ source
  • Viatris to acquire Pacira BioSciences for $1.65 billion, adding two non-opioid pain drugs
    Viatris announced Thursday it will purchase Pacira BioSciences for $1.65 billion in cash, paying $36.50 per share, a 45% premium to the prior close. The acquisition gives Viatris control of Pacira…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • FDA unveils transparency roadmap with plans for public NDA/BLA disclosures and inspection report publishing
    The FDA published a transparency roadmap that outlines its FY 2026 achievements and sets out priorities for FY 2027. One key priority is a proposal to require public disclosure of new drug applica…
    raps · 1mo agoRegulatoryNeutral↗ source
  • EU Commission urges EMA to fast-track Biotech Act preparations
    The European Commission has issued a statement urging the European Medicines Agency to accelerate work on the upcoming Biotech Act, which aims to streamline regulation of advanced therapies. The C…
    raps · 1mo agoRegulatoryNeutral↗ source
  • Caribou Biosciences explores strategic alternatives, drawing interest as a reverse-merger candidate
    Caribou Biosciences, the cell‑therapy company co‑founded by CRISPR pioneer Jennifer Doudna, announced it is evaluating strategic alternatives as it faces a difficult financing environment. The com…
    BioPharma Dive · 1mo agoDealNeutral↗ source
  • HHS unveils new vaccine injury surveillance plan with NIH clinic and reporting reimbursements
    The Department of Health and Human Services announced a comprehensive initiative to improve monitoring of vaccine-related injuries. The plan includes opening a new clinic at the National Institute…
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
  • Gardeners Basics Recalls Waltham 29 Broccoli Sprouting Seeds Due to Possible Salmonella Contamination
    October 8, 2026, Gardeners Basics of Spanish Fork, Utah, is recalling one-pound bags of broccoli sprouting seeds because they may be contaminated with Salmonella, an organism which can cause seriou…
    fda recalls · 1mo ago↗ source
  • Recon: FDA identifies four deaths in Newron schizophrenia drug trials; Dutch court blocks subcutaneous Keytruda in eight Europea...
    Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.
    raps · 1mo ago↗ source
  • Caribou Biosciences halts CAR-T programs and cuts staff amid funding shortfall
    Caribou Biosciences, a CRISPR gene-editing company co-founded by Nobel laureate Jennifer Doudna, announced it will stop work on its off-the-shelf CAR-T cancer therapies. The decision follows the c…
    BioPharma Dive · 1mo agoLayoffsNegative↗ source
  • Cerevance reports positive Phase 3 results for Parkinson’s drug solengepras
    Cerevance, a Boston biotech spinout from Takeda, announced that its experimental Parkinson’s drug solengepras achieved its primary endpoint in a Phase 3 trial. The trial enrolled 341 patients with…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • EMA to revise pharmacogenomics guideline as MHRA adopts AI framework for medical devices
    The European Medicines Agency’s Committee for Medicinal Products for Human Use is preparing a major revision of its 2018 guideline on good pharmacogenomic practices. Regulators say the rapid advan…
    raps · 1mo agoRegulatoryNeutral↗ source
  • Dutch court blocks Merck's subcutaneous Keytruda sales in eight European countries after Halozyme patent win
    A Netherlands court issued an injunction that stops Merck from marketing its subcutaneous formulation of Keytruda, known as Keytruda Qlex, in eight European markets. The ruling follows a patent in…
    BioPharma Dive · 1mo agoRegulatoryNeutral↗ source
  • Eden Brothers recalls Calabrese broccoli seeds over possible Salmonella contamination
    Eden Brothers LLC announced a recall of its Calabrese broccoli seeds after being informed by its supplier that the product may be contaminated with Salmonella. The recall includes 1‑ounce and 1‑po…
    fda recalls · 1mo agoCRLNegative↗ source
  • AbbVie/Genmab’s Epkinly halves progression risk in frontline DLBCL trial
    A Phase 3 study of the bispecific antibody Epkinly combined with standard chemotherapy showed nearly a 50% reduction in the risk of disease progression or death compared with chemotherapy alone in…
    BioPharma Dive · 1mo agoPositive readoutPositive↗ source
  • GE HealthCare to buy Sofie Biosciences for $945 million, boosting U.S. PET radiopharma capacity
    GE HealthCare announced it will acquire Sofie Biosciences for $945 million in cash, aiming to broaden its radiopharmaceutical manufacturing and distribution in the United States. Sofie Biosciences…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • Forbion raises $2.6 billion for two European biotech venture funds
    Forbion announced it has secured 2.3 billion euros ($2.6 billion) across two new venture funds, its largest raise to date. The funds, called Forbion Growth Opportunities IV and Forbion Ventures Fu…
    BioPharma Dive · 1mo agoDealPositive↗ source
  • ArriVent shares tumble as lung cancer trial of furmonertinib misses primary goal
    ArriVent BioPharma reported that its late-stage study of furmonertinib in patients with EGFR exon 20 insertion-mutated non-small cell lung cancer did not achieve its primary endpoint. The trial, w…
    BioPharma Dive · 1mo agoNegative readoutNegative↗ source
  • Nova Biomedical issues global correction for StatStrip Glucose Hospital Meter over software patient-ID error
    Nova Biomedical announced a global medical device correction for its StatStrip Glucose Hospital Meter System. The correction targets a software issue in the Gen 2.0 model that can leave prior pati…
    fda medwatch · 1mo agoCRLNegative↗ source
  • UK regulator adopts AI framework for medical devices and launches third AI Airlock phase
    The Medicines and Healthcare products Regulatory Agency (MHRA) announced that the UK government has adopted a set of recommendations on the use of artificial intelligence in medical devices. These…
    raps · 1mo agoRegulatoryNeutral↗ source
  • UK regulator adopts AI framework for medical devices, launches next phase of AI sandbox
    The Medicines and Healthcare products Regulatory Agency announced that the UK government has accepted a set of recommendations on using artificial intelligence in medical devices. These recommendat…
    raps · 1mo agoRegulatoryPositive↗ source